Journal of Internal Medicine Concepts & Practice >

2023 , Vol. 18 >Issue 04: 239 - 241

DOI: https://doi.org/10.16138/j.1673-6087.2023.04.005

Expert forum

Evolution of understanding of primary bilateral macronodular adrenal hyperplasia

Expand

Received date: 2023-05-30

  Online published: 2024-01-09

Fold

Cite this article

ZHOU Weiwei, WANG Weiqing . Evolution of understanding of primary bilateral macronodular adrenal hyperplasia[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(04) : 239 -241 . DOI: 10.16138/j.1673-6087.2023.04.005

References

[1] Bertherat J, Bourdeau I, Bouys L, et al. Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia[J]. Endocr Rev, 2023, 44(4): 567-628.
[2] Cavalcante IP, Berthon A, Fragoso MC, et al. Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease[J]. Nat Rev Endocrinol, 2022, 18(11): 699-711.
[3] Bouys L, Chiodini I, Arlt W, et al. Update on primary bilateral macronodular adrenal hyperplasia(PBMAH)[J]. Endocrine, 2021, 71(3): 595-603.
[4] Vassiliadi DA, Tsagarakis S. Diagnosis and management of primary bilateral macronodular adrenal hyperplasia[J]. Endocr Relat Cancer, 2019, 26(10): R567-R581.
[5] Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia[J]. N Engl J Med, 2013, 369(22): 2115-2125.
[6] Assié G, Libé R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome[J]. N Engl J Med, 2013, 369(22): 2105-2114.
[7] Gagliardi L, Schreiber AW, Hahn CN, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia[J]. J Clin Endocrinol Metab, 2014, 99(9): E1784-E1792.
[8] Faucz FR, Zilbermint M, Lodish MB, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation[J]. J Clin Endocrinol Metab, 2014, 99(6): E1113-E1119.
[9] Espiard S, Drougat L, Libé R, et al. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences[J]. J Clin Endocrinol Metab, 2015, 100(6): E926-E935.
[10] Elbelt U, Trovato A, Kloth M, et al. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma[J]. J Clin Endocrinol Metab, 2015, 100(1): E119-E128.
[11] Chasseloup F, Bourdeau I, Tabarin A, et al. Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome: a multicentre, retrospective, cohort study[J]. Lancet Diabetes Endocrinol, 2021, 9(12): 813-824.
[12] Vaczlavik A, Bouys L, Violon F, et al. KDM1A inactivation causes hereditary food-dependent Cushing syndrome[J]. Genet Med, 2022, 24(2): 374-383.
[13] Violon F, Bouys L, Berthon A, et al. Impact of morphology in the genotype and phenotype correlation of bilateral macronodular adrenocortical disease(BMAD)[J]. Endocr Pathol, 2023, 34(2): 179-199.
[14] Lacroix A. Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing’s syndrome[J]. Eur J Endocrinol, 2023, 188(3): R56-R72.
[15] Meloche-Dumas L, Mercier F, Lacroix A. Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome[J]. Best Pract Res Clin Endocrinol Metab, 2021, 35(2): 101486.
[16] Rubinstein G, Osswald A, Braun LT, et al. The role of adrenal venous sampling(AVS) in primary bilateral macronodular adrenocortical hyperplasia (PBMAH): a study of 16 patients[J]. Endocrine, 2022, 76(2): 434-445.
[17] Zhang R, Rubinstein G, Vetrivel S, et al. Steroid profiling using liquid chromatography mass spectrometry during adrenal vein sampling in patients with primary bilateral macronodular adrenocortical hyperplasia[J]. Front Endocrinol (Lausanne), 2022, 13: 1079508.
[18] Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral adrenalectomy as a first-line treatment of Cushing’s syndrome in patients with primary bilateral macronodular adrenal hyperplasia[J]. J Clin Endocrinol Metab, 2015, 100(12): 4417-4424.
[19] Osswald A, Quinkler M, Di Dalmazi G, et al. Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy[J]. J Clin Endocrinol Metab, 2019, 104(7): 2985-2993.
[20] Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing’s syndrome[J]. N Engl J Med, 1997, 337(20): 1429-1434.
[21] St-Jean M, Bourdeau I, Martin M, et al. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2021, 106(1): e45-e60.
Options
Outlines

/

〈 〉